A study of Entecavir in Blacks/African Americans and Hispanics with chronic HBV infection.

This study is being done to estimate the proportion of subjects who achieve an HBV DNA < 50 IU/mL (approximately 300 copies/mL) at Week 48 of ETV treatment.

You may be eligible to participate in this study if you:

• Have a chronic HBV infection
• Are nucleoside/tide-naïve
• Are Black/African Americans or Hispanic

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.